Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Pochamana Phisalprapa, Chayanis Kositamongkol, Julajak Limsrivilai, Satimai Aniwan, Phunchai Charatcharoenwitthaya, Pises Pisespongsa, Taya Kitiyakara, Suporn Treepongkaruna & Nathorn Chaiyakunapruk. (2020) Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand. Journal of Medical Economics 23:11, pages 1302-1310.
Read now
Read now
Tawnya Hansen & Laura E. Targownik. (2016) Ustekinumab for the treatment of Crohn’s disease. Expert Review of Gastroenterology & Hepatology 10:9, pages 989-994.
Read now
Read now
Articles from other publishers (28)
Cheng-Jun Li, Yi-Kai Wang, Shun-Ming Zhang, Mu-Dan Ren & Shui-Xiang He. (2023) Global burden of inflammatory bowel disease 1990-2019: A systematic examination of the disease burden and twenty-year forecast. World Journal of Gastroenterology 29:42, pages 5764-5780.
Crossref
Crossref
Cheng-Jun Li, Yi-Kai Wang, Shun-Ming Zhang, Mu-Dan Ren & Shui-Xiang He. (2023) Global burden of inflammatory bowel disease 1990-2019: A systematic examination of the disease burden and twenty-year forecast. World Journal of Gastroenterology 29:42, pages 5751-5767.
Crossref
Crossref
Shreyak Sharma, Darrick K Li, Louis J Levine, Abdelkader Chaar, Chandler McMillan, Jill K J Gaidos, Deborah D Proctor & Badr Al-Bawardy. (2023) Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis. Crohn's & Colitis 360 5:3.
Crossref
Crossref
Johan Burisch, Mirabella Zhao, Selwyn Odes, Peter De Cruz, Severine Vermeire, Charles N Bernstein, Gilaad G Kaplan, Dana Duricova, Dan Greenberg, Hans O Melberg, Mamoru Watanabe, Hyeong Sik Ahn, Laura Targownik, Valérie E H Pittet, Vito Annese, KT Park, Konstantinos H Katsanos, Marte L Høivik, Zeljko Krznaric, María Chaparro, Edward V LoftusJrJr, Peter L Lakatos, Javier P Gisbert, Willem Bemelman, Bjorn Moum, Richard B Gearry, Michael D Kappelman, Ailsa Hart, Marieke J Pierik, Jane M Andrews, Siew C Ng, Renata D'Inca & Pia Munkholm. (2023) The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology & Hepatology 8:5, pages 458-492.
Crossref
Crossref
Rui Wang, Zhaoqi Li, Shaojun Liu & Decai Zhang. (2023) Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open 13:3, pages e065186.
Crossref
Crossref
Naazish S. Bashir, Avery Hughes & Wendy J. Ungar. (2023) Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review. MDM Policy & Practice 8:1.
Crossref
Crossref
Kate E. Lee, Francesca Lim, Adam S. Faye, Bo Shen & Chin Hur. (2022) Endoscopic Balloon Dilation Is Cost-Effective for Crohn’s Disease Strictures. Digestive Diseases and Sciences 67:12, pages 5462-5471.
Crossref
Crossref
Jiaqi Yao, Xinchan Jiang & Joyce H S You. (2021) Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost‐effectiveness analysis. Journal of Gastroenterology and Hepatology 36:9, pages 2397-2407.
Crossref
Crossref
Tomas Mlcoch, Barbora Decker & Tomas Dolezal. (2021) Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn’s Disease. Applied Health Economics and Health Policy 19:4, pages 593-604.
Crossref
Crossref
Hongli Zhou, Xiaojing Zeng, Dongchen Sun, Zhe Chen, Weixin Chen, Liwei Fan, Yanin Limpanont, Paron Dekumyoy, Wanchai Maleewong & Zhiyue Lv. (2021) Monosexual Cercariae of Schistosoma japonicum Infection Protects Against DSS-Induced Colitis by Shifting the Th1/Th2 Balance and Modulating the Gut Microbiota. Frontiers in Microbiology 11.
Crossref
Crossref
Sang Hyoung Park, Jae Cheol Park, Milan Lukas, Martin Kolar & Edward V. Loftus. (2020) Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases. Intestinal Research 18:1, pages 34-44.
Crossref
Crossref
Laura E Targownik, Eric I Benchimol, Julia Witt, Charles N Bernstein, Harminder Singh, Lisa Lix, Aruni Tennakoon, Antonio Aviña Zubieta, Stephanie Coward, Jennifer Jones, Ellen Kuenzig, Sanjay K Murthy, Geoffrey C Nguyen, Juan Nicolás Peña-Sánchez & Gil Kaplan. (2019) The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease. Inflammatory Bowel Diseases 25:10, pages 1718-1728.
Crossref
Crossref
Adrián H. TeruelÉdgar Pérez-Esteve, Isabel González-Álvarez, Marta González-Álvarez, Ana M. Costero, Daniel Ferri, Pablo Gaviña, Virginia Merino, Ramón Martínez-Máñez & Félix Sancenón. (2019) Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease. Molecular Pharmaceutics 16:6, pages 2418-2429.
Crossref
Crossref
Sruthi Vijaya Retnakumar & Sylviane Muller. (2019) Pharmacological Autophagy Regulators as Therapeutic Agents for Inflammatory Bowel Diseases. Trends in Molecular Medicine 25:6, pages 516-537.
Crossref
Crossref
Zunirah Ahmed, Shashank Sarvepalli, Ari Garber, Miguel Regueiro & Maged K Rizk. (2019) Value-Based Health Care in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 25:6, pages 958-968.
Crossref
Crossref
Shellie Jean Radford. (2019) Fatigue in inflammatory bowel disease: understanding research needs through an exploratory narrative review. Gastrointestinal Nursing 17:4, pages 30-35.
Crossref
Crossref
Hamid Asadzadeh Aghdaei, Azade Amini Kadijani, Dario Sorrentino, Alireza Mirzaei, Shabnam Shahrokh, Hedieh Balaii, Marco Geraci & Mohammad Reza Zali. (2018) An increased Bax/Bcl‐2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients. United European Gastroenterology Journal 6:7, pages 1074-1081.
Crossref
Crossref
Przemysław Holko, Paweł Kawalec & Andrzej Pilc. (2018) Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist. PharmacoEconomics 36:7, pages 853-865.
Crossref
Crossref
Lachaine Jean, Miron Audrey, Catherine Beauchemin & on behalf of the iGenoMed Consortium. (2018) Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review. Canadian Journal of Gastroenterology and Hepatology 2018, pages 1-14.
Crossref
Crossref
Jung‐Wook Kim, Chang Kyun Lee, Sang Youl Rhee, Chi Hyuck Oh, Jae‐Jun Shim & Hyo Jong Kim. (2018) Trends in health‐care costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: A nationwide population‐based study. Journal of Gastroenterology and Hepatology 33:4, pages 847-854.
Crossref
Crossref
Christina Y. Ha & Asher Kornbluth. 2018. Treatment of Inflammatory Bowel Disease with Biologics. Treatment of Inflammatory Bowel Disease with Biologics
261
282
.
Laura E. Targownik, Aruni Tennakoon, Stella Leung, Lisa M. Lix, Zoann Nugent, Harminder Singh & Charles N. Bernstein. (2017) Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD. Inflammatory Bowel Diseases 23:3, pages 409-420.
Crossref
Crossref
Paulo Gustavo KotzeSubrata GhoshWillem A. BemelmanRemo Panaccione. (2017) Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls. Intestinal Research 15:2, pages 160.
Crossref
Crossref
Laura E. Targownik & Charles N. Bernstein. 2017. Inflammatory Bowel Disease. Inflammatory Bowel Disease
345
355
.
Karoline Freeman, Martin Connock, Peter Auguste, Sian Taylor-Phillips, Hema Mistry, Deepson Shyangdan, Rachel Court, Ramesh Arasaradnam, Paul Sutcliffe & Aileen Clarke. (2016) Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn’s disease: systematic reviews and economic modelling. Health Technology Assessment 20:83, pages 1-288.
Crossref
Crossref
Christina Y. Ha & Asher Kornbluth. (2016) A Critical Review of Biosimilars in IBD. Inflammatory Bowel Diseases 22:10, pages 2513-2526.
Crossref
Crossref
Pierre-Olivier Blotière, Jérémie Rudant, Amélie Barré, Antoine Racine, Alain Weill, Laurent Peyrin-Biroulet, Franck Carbonnel & François Alla. (2016) Conditions of prescription of anti-TNF agents in newly treated patients with inflammatory bowel disease in France (2011–2013). Digestive and Liver Disease 48:6, pages 620-625.
Crossref
Crossref
Gilaad G. Kaplan. (2015) The global burden of IBD: from 2015 to 2025. Nature Reviews Gastroenterology & Hepatology 12:12, pages 720-727.
Crossref
Crossref